HIMS Soars 7.3% on Bullish Guidance and Analyst Hype—What’s Next for the Telehealth Giant?

Summary
• Hims & Hers Health (HIMS) surges 7.26% to $47.69, hitting an intraday high of $48.09
• Deutsche Bank raises price target to $48, BofA notes incremental optimism on GLP-1 franchise
• Stock trades 31.6% below 52-week high but up 86.6% year-to-date

Shares of Hims & Hers Health are surging on a mix of strong revenue guidance and analyst upgrades, defying a broader healthcare sector that remains mixed. The stock’s 7.3% rally has pushed it closer to its 52-week high, but lingering volatility and a bearish MACD signal suggest caution for traders. With options activity heating up, the question is whether this momentum can sustain or if it’s a short-term bounce.

Revenue Guidance and Analyst Upgrades Fuel HIMS Rally
Hims & Hers Health’s 7.3% intraday surge is driven by two key catalysts: the company’s reaffirmed FY2025 revenue guidance of $2.3–$2.4 billion and Deutsche Bank’s upgraded price target to $48. Despite BofA maintaining an 'Underperform' rating, its incremental optimism on the GLP-1 franchise has provided tailwinds. The stock’s momentum follows a 6.4% drop 16 days ago amid broader market profit-taking, suggesting investors are capitalizing on a perceived short-term rebound in telehealth demand and regulatory optimism.

Healthcare Sector Splits as HIMS Defies Peers
While HIMS surges, its sector leader Teladoc Health (TDOC) declines 1.55%, highlighting divergent investor sentiment. The healthcare sector remains fragmented, with UnitedHealth’s 7% rally driven by Warren Buffett’s investment and Medicaid policy shifts. HIMS’s telehealth focus appears to benefit from GLP-1-related optimism, whereas broader healthcare providers face pressure from Medicaid cuts and rural ER staffing challenges. This divergence underscores the stock’s unique positioning in the GLP-1 space.

Options and ETFs to Watch: Capitalizing on HIMS’s Volatility
• MACD: -2.65 (bearish), Signal Line: -2.54, Histogram: -0.11
• RSI: 40.05 (oversold), Bollinger Bands: $39.48–$52.27, 200D MA: $41.12 (below current price)

HIMS is in a short-term bullish trend but remains in a long-term range. Key support at $43.99–$44.49 and resistance at $48.09–$52.27 define the trading range. With RSI at oversold levels and a bearish MACD, the stock may retest support before resuming its upward bias. The VanEck Semiconductor ETF (XSD) is not relevant here, but high-liquidity options offer leverage.

Top Options Picks:
• HIMS20250912C47 (Call, $47 strike, 9/12 expiry):
- IV: 66.88% (moderate), Leverage: 18.11%, Delta: 0.6166 (moderate), Theta: -0.2341 (high time decay), Gamma: 0.0755 (high sensitivity), Turnover: $517,796
- This call offers a balance of leverage and liquidity, ideal for a 5% upside scenario (targeting $50.07). A 5% move would yield a payoff of $3.07 per contract, with gamma amplifying gains as the stock rises.
• HIMS20250912C48 (Call, $48 strike, 9/12 expiry):
- IV: 68.73% (moderate), Leverage: 22.10%, Delta: 0.5384 (moderate), Theta: -0.2261 (high time decay), Gamma: 0.0764 (high sensitivity), Turnover: $549,502
- This contract provides higher leverage and strong gamma, making it a top pick for aggressive bulls. A 5% upside would generate a $2.07 payoff, with theta decay manageable given the 9/12 expiry.

Hook: Aggressive bulls may consider HIMS20250912C47 into a bounce above $48.09.

Backtest Hims & Hers Health Stock Performance

HIMS at a Pivotal Juncture—Act Now on Bullish Momentum
HIMS’s 7.3% rally is a mix of optimism and caution. While the stock’s 52-week high remains out of reach, the oversold RSI and bearish MACD suggest a potential pullback to test support at $43.99. Traders should monitor the 200-day MA ($41.12) as a critical level; a break below could reignite bearish sentiment. Meanwhile, Teladoc Health’s -1.55% decline highlights sector fragility. For those bullish, the HIMS20250912C47 and C48 options offer high-leverage entry points. Act now: Watch for a breakout above $48.09 or a breakdown below $43.99 to dictate next steps.